Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.

ABSTRACT:

Background

Omadacycline offers a potential advancement in the management of infections in people with cystic fibrosis (CF) because of its spectrum of activity, intrapulmonary penetration, and oral bioavailability. A prospective single-dose, single-arm study was conducted to characterize the pharmacokinetic (PK) profile of omadacycline in people with CF, considering the known alterations in PK observed in this population (NCT04460586, 2020-07-01).

Methods

Plasma samples were obtained from nine adults with CF who received a single dose of intravenous omadacycline 100 mg over 0.5 h followed by a 1-week washout and an oral dose of omadacycline 300 mg. The data were analyzed using noncompartmental PK.

Results

The maximum plasma concentration (C_max) and area unde

SUBMITTER: Sanders M 

PROVIDER: S-EPMC11649715 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature